Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Tunica Albuginea who wrote (4420)	1/8/1998 6:24:00 PM
From: BigKNY3	Respond to of 23519

TA: <<the FDA is now taking a harder look at what they approve>> TA: I totally disagree with you. The fallout from Redux will have no effect on how the FDA approves drugs, particularly those drugs that are not related to Redux. As an example, on November 11, 1997, the FDA approved Merida (sibutramine) for the treatment of obesity. This SNRI barely made it out of its panel review meeting.http://www.pslgroup.com/dg/daba.htm. How do you explain this approval under your "new" FDA harder look environment? BigKNY3